Two experimental vaccines should be added to an Ebola trial, World Health Organization expert groups have recommended. WHO Director-General Tedros Adhanom Ghebreyesus announced the recommendation on November 4, RTÉ News and Euronews reported.

The candidates target Bundibugyo, the virus responsible for the outbreak, for which there is no approved vaccine. Oxford University developed one candidate, ChAdOx1 BDBV, with the Serum Institute of India; the other is Moderna’s mRNA-1469. The recommendation is for clinical testing, not authorization for general use.

According to RTÉ, the trial started in October with Ervebo. That vaccine has approval against Ebola virus, but not against Bundibugyo. The trial is led by the DRC’s National Institute for Biomedical Research, with WHO among its supporting partners.

RTÉ cited figures released that week by Africa CDC showing 10,444 confirmed cases and more than 5,300 deaths across Africa. Most deaths were in the Democratic Republic of Congo, and the reported fatality rate exceeded 50%.

Euronews also reported infections in Kenya, Nigeria and Uganda. Ghana and the United States were among countries restricting travel from the DRC, the outlet said. Tedros called for those restrictions to end, warning that they undermine the response and discourage countries from reporting outbreaks openly.

Tedros emphasized that vaccine research does not remove the need for established outbreak controls: treating people early, identifying their contacts, isolating patients, conducting burials safely and respectfully, and building trust with affected communities.